Durable PSA Control After Testosterone Recovery in High‑Risk Biochemical Recurrent Prostate Cancer
A recent post hoc analysis of the phase 3 EMBARK trial in high‑risk biochemical recurrent prostate cancer has generated considerable interest because it suggests that durable, long‑term PSA control can occur even after testosterone has fully recovered to eugonadal levels, challenging the conventional assumption that hormonal suppression must be continuous to maintain remission. The analysis […]
